Search results for "cost-effectiveness"

showing 10 items of 72 documents

Optimization of hepatitis C virus screening strategies by birth cohort in Italy

2020

Abstract Background and Aims Cost‐effective screening strategies are needed to make hepatitis C virus (HCV) elimination a reality. We determined if birth cohort screening is cost‐effective in Italy. Methods A model was developed to quantify screening and healthcare costs associated with HCV. The model‐estimated prevalence of undiagnosed HCV was used to calculate the antibody screens needed annually, with a €25 000 cost‐effectiveness threshold. Outcomes were assessed under the status quo and a scenario that met the World Health Organization's targets for elimination of HCV. The elimination scenario was assessed under five screening strategies. Results A graduated birth cohort screening strat…

medicine.medical_specialtyCost effectivenessCost-Benefit AnalysisHepatitis C virusSettore SECS-P/06cost-effectiveneHepacivirusmedicine.disease_causeAntiviral AgentsWorld healthNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansMass Screeningcost-effectivenessAntibody screensHepatologyUnder-fivebusiness.industryscreeningHealth services researchhealthcost‐effectivenessHepatitis C ChronicHepatologyHepatitis CItaly030220 oncology & carcinogenesisSettore MED/42HCVOriginal Articleepidemiology030211 gastroenterology & hepatologyLiver Disease and Public HealthQuality-Adjusted Life YearsBirth cohortbusinessWHO targetscost-effectiveness HCV screening WHO targetsDemography
researchProduct

HCV eradication: a duty of the State, an option for the individual

2020

In recent years, the debate on ethical issues related to hepatitis C virus therapies has been focused on the problem of drug prices and access to therapies. Nonetheless, the goal of hepatitis C virus eradication set by the World Health Organization in 2016 is raising new ethical issues, since governments are faced with a new challenge: reaching through screening, diagnosis and treatment a large amount of subjects with undiagnosed hepatitis C infection. National governments, especially high-income countries with a Welfare State, are compelled to provide access to therapies, but also to involve those who are still unaware of their disease status. Since people cannot be forced but should be gu…

medicine.medical_specialtyCost effectivenessmedia_common.quotation_subjectHepatitis C virusmedicine.disease_causeSettore MED/02 - Storia Della Medicina03 medical and health sciences0302 clinical medicineState (polity)Settore MED/43 - Medicina Legalemedicinehcv030212 general & internal medicineEthicIntensive care medicineDutyAutonomymedia_commonEradicationEthical issuesbusiness.industryWelfare stateHepatitis Cmedicine.diseaseCost-effectivenessbusinessAutonomy
researchProduct

Cost effectiveness analysis of childhood obesity primary prevention programmes: a systematic review

2022

Background. Childhood obesity is associated with enormous health consequences and costs to society. This study aims to systematically review the studies on Cost Effectiveness Analysis (CEA) of primary prevention programmes of childhood obesity, discussing the gaps and providing recommendations for future research. Methods. All the studies on the cost effectiveness evaluation of primary prevention of obesity among children were included. Studies were retrieved from MEDLINE and Google Scholar, up to 31st March 2012, with only English language papers being eligible. The quality of the retrieved studies was evaluated by using the Drummond scale. Re…

medicine.medical_specialtyCost effectivenessprimary preventionAlternative medicineMEDLINEsystemic reviewOverweightSettore MED/42 - Igiene Generale E ApplicataChildhood obesityIntervention (counseling)medicineoverweightcost-effectivenesslcsh:R5-920business.industrylcsh:Public aspects of medicinelcsh:RA1-1270Cost-effectiveness analysismedicine.diseaseScale (social sciences)Family medicinePhysical therapymedicine.symptombusinesslcsh:Medicine (General)childhood obesitycost-effectiveness childhood obesity overweight primary prevention systemic reviewEpidemiology Biostatistics and Public Health
researchProduct

Closed Incision Negative Pressure Therapy Achieves Better Outcome Than Standard Wound Care: Clinical Outcome and Cost-Effectiveness Analysis in Open …

2020

BackgroundSurgical site infections (SSIs) and surgical site occurrences (SSOs) are frequent post-operative complications that are dependent on the presence of different risk factors. The use of closed incision negative pressure therapy (ciNPT) is considered a measure by the WHO guidelines for prevention of SSIs. The prevention of SSOs is an extremely important issue in the ventral hernia repair (VHR) surgical field. SSO onset not only affects the patient's quality of life, but can also cause the onset of life-threatening conditions that may require re-hospitalization, re-intervention and often mesh removal. Such outcome can become extremely costly, contributing to increased health care cost…

medicine.medical_specialtyCost effectivenessventral hernia repair030204 cardiovascular system & hematology03 medical and health sciencesWound care0302 clinical medicineQuality of lifeEpidemiologyMedicineguidelinescost-effectivenesssurgical site occurrencesbusiness.industryMedical recordGeneral Engineeringsurgical site infectionsCost-effectiveness analysisabdominal surgeryQuality ImprovementSurgeryRelative riskGeneral Surgeryoutcomeclosed incision negative pressure therapyPreventive Medicinebusiness030217 neurology & neurosurgeryAbdominal surgery
researchProduct

Cost-effectiveness analysis of robot-assisted vs. open partial nephrectomy

2017

Background The cost-effectiveness of robot-assisted partial nephrectomy (RAPN) vs. the open procedure is not established. Methods We estimated in-hospital complications and the cost of RAPN vs. open partial nephrectomy (OPN) using an economic model. Costs incurred both intraoperatively and in hospital were considered. US data were extracted from existing literature. Results Mean in-hospital costs were $14,824 (95% CI $13,368-$16,898) for RAPN and $15,094 (95% CI $13,491-$17,140) for OPN. Complications after RAPN occurred in 23.3% (95% CI 20.0-25.8%) and after OPN in 36.1% (95% CI 35.6-36.6%) of the patients. In a sensitivity analysis, limited centre experience was associated with relevant i…

medicine.medical_specialtyCost-Benefit Analysismedicine.medical_treatment030232 urology & nephrologyBiophysicsNephrectomy03 medical and health sciencesPostoperative Complications0302 clinical medicineRobotic Surgical ProceduresmedicineHumansOpen partial nephrectomyHospital CostsComputer-assisted surgerybusiness.industryDecision TreesPerioperativeCost-effectiveness analysisNephrectomyComputer Science ApplicationsSurgeryModels EconomicTreatment Outcome030220 oncology & carcinogenesisSurgeryLower costbusinessThe International Journal of Medical Robotics and Computer Assisted Surgery
researchProduct

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy

2016

ABSTRACT Objective: To evaluate the cost-effectiveness of bedaquiline plus background drug regimens (BR) for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. Methods: A Markov model was adapted to the Italian setting to estimate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR in the treatment of MDR-TB and XDR-TB over 10 years, from both the National Health Service (NHS) and societal perspective. Cost-effectiveness was evaluated in terms of life-years gained (LYG). Clinical data were sourced from trials; resource consumption for compared treatments was modelled according to advice from an expert c…

medicine.medical_specialtyPediatricsTuberculosisCost effectivenessBedaquilinelcsh:Business03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSocietal perspectivemedicineOriginal Research Article030212 general & internal medicineResource consumptionSensitivity analysescost-effectivenessDisease treatmenthealth care economics and organizationsbusiness.industrylcsh:Public aspects of medicinelcsh:RA1-1270medicine.diseaseNational health serviceMDR tuberculosis030228 respiratory systemchemistryItalyEmergency medicineXDR tuberculosisOriginal ArticleBedaquilinebusinesslcsh:HF5001-6182Journal of Market Access & Health Policy
researchProduct

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart diseas…

2013

AIMS: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD).METHODS AND RESULTS: Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prev…

medicine.medical_specialtyStatinAtherosclerosis; Cardiovascular disease; Cholesterol; Coronary heart disease; Low-density lipoproteinSettore MED/09 - Medicina Internamedicine.drug_classPopulationCHILDRENFamilial hypercholesterolemiaBile acid bindingCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyLDL-CHOLESTEROLDIAGNOSIS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicineMANAGEMENT030212 general & internal medicineeducationHealth aging / healthy living Cardiovascular diseases [IGMD 5]Alirocumabeducation.field_of_studyCYTOKINE PATTERN CHANGEbusiness.industryLow-density lipoproteinmedicine.diseaseAtherosclerosisCardiovascular diseaseLomitapideDENSITY-LIPOPROTEIN APHERESIS3. Good healthASSOCIATION EXPERT PANELCoronary heart diseaseEndocrinologyCholesterolchemistryCARDIOVASCULAR-DISEASEAtherosclerosiCardiology and Cardiovascular MedicinebusinessSTATIN TREATMENTmedicine.drugEuropean Heart Journal
researchProduct

Efficiency of telemedicine for acute stroke: a cost-effectiveness analysis from a French pilot study

2020

AbstractObjectivesTelestroke is an effective way to improve care and health outcomes for stroke patients. This study evaluates the cost-effectiveness of a French telestroke network.MethodsA decision analysis model was built using population-based data. We compared short-term clinical outcomes and costs for the management of acute ischemic stroke patients before and after the implementation of a telestroke network from the point of view of the national health insurance system. Three effectiveness endpoints were used: hospital death, death at 3 months, and severe disability 3 months after stroke (assessed with the modified Rankin scale). Most clinical and economic parameters were estimated fr…

medicine.medical_specialtyTelemedicineCost effectivenessCost-Benefit AnalysisPopulationPilot Projects030204 cardiovascular system & hematologyEfficiency OrganizationalState MedicineDisability Evaluation03 medical and health sciences0302 clinical medicineModified Rankin ScaleHumansMedicineHospital MortalityeducationStrokeTelerehabilitationAcute strokeeducation.field_of_studybusiness.industryHealth PolicyStroke RehabilitationCost-effectiveness analysismedicine.diseaseStrokeModels EconomicEmergency medicineFranceHealth Expendituresbusiness030217 neurology & neurosurgeryDecision analysisInternational Journal of Technology Assessment in Health Care
researchProduct

Photobiomodulation and myofascial temporomandibular disorder: Systematic review and meta-analysis followed by cost-effectiveness analysis

2021

Background Photobiomodulation (PBM) is a non-invasive and non-pharmacological treatment, which, has shown beneficial results in the treatment of temporomandibular disorders (TMD) related pain. This systematic review and meta-analysis study aimed to evaluate the efficacy of photobiomodulation in the treatment of myofascial pain associated with (TMD by analyzing randomized clinical trials published from 2007 to February 2019. The secondary objective of the study was to perform a cost-effectiveness analysis of TMD treatment with photobiomodulation in patients with myofascial pain. Material and methods International databases were used: Pubmed, Medline and Web of Science; the initial search rai…

medicine.medical_specialtybusiness.industryTemporomandibular disorderMEDLINEOrthodonticsCost-effectiveness analysisReviewPlacebolaw.inventionQuality of evidenceRandomized controlled trialLaser therapylawMeta-analysisPhysical therapyMedicinebusinessGeneral DentistryUNESCO:CIENCIAS MÉDICASJournal of Clinical and Experimental Dentistry
researchProduct